Further, IFN-β, a common treatment for MS, was demonstrated to induce the differentiation and function of the FoxA1 Treg cell subtype, suggesting a possible FoxA1-mediated mechanism for the efficacy of IFN-β treatment [125]. This evidence concerns the gene FOXA1 and myeloid sarcoma.